Skip to content
webinar

Webinar: Denmark as a location for clinical trials in hematology

Invest in Denmark and Innovation Center Denmark in Boston, in collaboration with Trial Nation, invite you to an exclusive webinar & roundtable discussion: “Denmark as a location for Clinical trials in Hematology”.

Where do you go to conduct the clinical trials that your business depends on?

For a growing number of the world’s major life science companies, the answer is Denmark. Let us provide you with an virtual introduction to the reasons why Denmark is such a great location for hematology clinical trials in this exclusive webinar.

Partner webinar collaboration with Trial Nation

Trial Nation offers a single, national entry point for life science companies, patient organizations and clinical researchers wishing to sponsor, participate in, and conduct clinical trials in Denmark. 

Webinar info How to Register? 

The webinar will be held Thursday the 27 May 2021 from 10:00-11:00 AM EST in collaboration with Trial Nation.

Webinar programme

An introduction to Trial Nation by CEO Marianne Pilgaard, describing their services towards global companies and clinical researchers wishing to conduct clinical trials in Denmark. 
 
Presentation of the hematologic clinical sites in Denmark by Dr. Abildgaard. The presentation will include statistics on prevalence and patient population with hematologic cancers. Dr. Abildgaard will also focus on Odense University Hospital, where he is in charge of research and clinical trials and his departments capabilities. He will especially focus on the newly established Elite Research Center for Cellular Immuno-therapy in Hematological Cancer (CITCO).     
 
Presentation of the work on immunotherapy (CAR-T) and bi-specific antibodies, and hemopoietec stem cell transplantation undertaken in Denmark by Dr. Hutchings. Dr. Hutchings, who is also responsible for the Phase I unit at Copenhagen University Hospital (Rigshospitalet), will also focus the first-in-human experiences and capabilities at the site. Lastly, he will spent some time on the latest breakthrough study using bi-specific antibody treatment (glofitamab) in lymphoma patients published in Journal of Clinical Oncology.   
 

get to know the Speakers

Dr. Niels Abildgaard

Clinical professor Niels Abildgaard is a hematologist. He is a responsible for treatment of myelomatose and Head of the Clinical Research Unit at Odense University Hospital. Professor Aabildgaard is furthermore Head of the Danish Myelomatoses Study Group and Medical Lead for Trial Nation Center for Hematology. 

Dr. Martin Hutchings

Senior Consultant Martin Hutchings is a haemato-oncologist. He is responsible for treatment of malignant lymphoma and for phase I treatment of haematological malignancies at Copenhagen University Hospital (Rigshospitalet). The clinic has recruited the first patient world-wide for 6 of the 12 latest clinical trials. Dr. Hutchings is furthermore Head of service for Hodgkin lymphoma, Mantle cell lymphoma and Castleman’s disease.

 

facts Why conduct clinical trials in Denmark?

  • A keen political commitment to the life sciences industry

  • One of the strongest economies in Europe, ranked no. 1 for ease of doing business

  • Continuous optimisation of clinical trial processes and procedures

  • Highly qualified and motivated workforce with many Master’s degrees and PhD graduates

  • Access to biobanks and registries of patient data

  • High willingness in the population to participate in research

Get in touch Are you interested in a 1-1 meeting prior to or after the webinar or have specific questions that you would like the speakers to address?

Please contact our dedicated advisors here:

Loading...